IDX184

prodrug to enhance formation in the liver of the active triphosphate of 2'-methylguanosine, a potent and specific polymerase inhibitor of the hepatitis C virus; structure in first source

Also Known As:

2'-C-methylguanosine monophosphate

Networked: 4 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleotides: 140
        Guanine Nucleotides: 675
        Guanosine Monophosphate: 884
        IDX184: 4
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Ribonucleotides: 307
    - Guanine Nucleotides: 675
      - Guanosine Monophosphate: 884
        IDX184: 4
  - Purine Nucleotides: 140
    - Guanine Nucleotides: 675
      - Guanosine Monophosphate: 884
        IDX184: 4

Experts

1.	Chen, Jie: 2 articles (01/2013 - 12/2012)
2.	Dubuc-Patrick, Gloria: 2 articles (01/2013 - 12/2012)
3.	Lalezari, Jacob: 2 articles (01/2013 - 12/2012)
4.	Lawrence, Shannon: 2 articles (01/2013 - 12/2012)
5.	Mayers, Douglas: 2 articles (01/2013 - 12/2012)
6.	McCarville, Joseph: 2 articles (01/2013 - 12/2012)
7.	Pietropaolo, Keith: 2 articles (01/2013 - 12/2012)
8.	Sullivan-Bólyai, John: 2 articles (01/2013 - 12/2012)
9.	Zhou, Xiao-Jian: 2 articles (01/2013 - 12/2012)
10.	Badaroux, Eric: 1 article (01/2015)

Related Diseases

1.	Chronic Hepatitis C 01/01/2013 - "IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C." 12/01/2012 - "This study investigated the safety, tolerability, antiviral activity, and pharmacokinetics of IDX184 as a single agent in treatment-naïve patients with genotype-1 chronic hepatitis C virus (HCV) infection. " 12/01/2012 - "Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection." 01/01/2015 - "The most promising compound, namely the O-[S-(hydroxyl)pivaloyl-2-thioethyl]{abbreviated as O-[(HO)tBuSATE)]} N-benzylamine phosphoramidate diester derivative (IDX184), was selected for further in vivo studies, and was the first clinical pronucleotide evaluated for the treatment of chronic hepatitis C up to Phase II trials."
2.	Infections 12/01/2012 - "This study investigated the safety, tolerability, antiviral activity, and pharmacokinetics of IDX184 as a single agent in treatment-naïve patients with genotype-1 chronic hepatitis C virus (HCV) infection. "
3.	Hepatitis C 01/01/2015 - "The assay was successfully applied to pharmacokinetic studies of 2'-MeGTP in liver tissue samples after single oral doses of IDX184, a nucleotide prodrug inhibitor of the viral polymerase for the treatment of hepatitis C, to mice. "
4.	Virus Diseases (Viral Diseases) 12/01/2012 - "Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection."

Related Drugs and Biologics

1.	Hydroxyl Radical
2.	Antiviral Agents (Antivirals)
3.	ProTides
4.	benzylamine
5.	phosphoramidic acid
6.	Ribavirin (Virazole)
7.	Nucleotides